Skip to main content
Top
Published in: Rheumatology International 4/2010

01-02-2010 | Short Communication

Gender differences in the relationship of anti-parvovirus B19 IgG with antinuclear antibody and C-reactive protein in clinical adult serum samples

Authors: Thomas A. O’Bryan, Stanley J. Naides

Published in: Rheumatology International | Issue 4/2010

Login to get access

Abstract

Human parvovirus B19 (B19) infection is often suspected as an etiologic agent in a variety of rheumatologic diseases. It has been hypothesized that this virus potentially induces immune dysregulation by abnormal cytokine expression in susceptible hosts. The objective of this study is to examine the relationship between anti-parvovirus B19 IgG antibody (B19 IgG) and two common markers of immune dysregulation—antinuclear antibody (ANA) and C-reactive protein (CRP) in clinical sera. Qualitative B19 IgG antibody and levels of high-sensitivity CRP were determined in adult serum samples submitted to a university hospital clinical laboratory for ANA testing. Prevalence of B19 IgG was compared among groups by ANA status and CRP tertile. B19 IgG was detected in 72.3% of 318 samples. Among women above the first quartile of age (>38 years), presence of B19 IgG was associated with CRP tertile rank (P = 0.008) and CRP levels ≥1 mg/L (P = 0.001) independent of age and ANA status. B19 IgG was less frequent in ANA-positive than ANA-negative women ≤38 years of age (P = 0.009). Viral antibody was not associated with either biomarker in men. These data suggest parvovirus B19 infection may be associated with chronic inflammation in some women after the third decade of life.
Literature
1.
go back to reference Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A (2008) Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8:116–120CrossRefPubMed Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A (2008) Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8:116–120CrossRefPubMed
3.
go back to reference Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O, Hirano T, Sugamura K (1996) A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70:8485–8491PubMed Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O, Hirano T, Sugamura K (1996) A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70:8485–8491PubMed
4.
go back to reference Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, Sasaki T (2002) Regulation of tumor necrosis factor alpha promotor by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76:5395–5403CrossRefPubMed Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, Sasaki T (2002) Regulation of tumor necrosis factor alpha promotor by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76:5395–5403CrossRefPubMed
5.
go back to reference Mitchell LA (2002) Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 67:267–274CrossRefPubMed Mitchell LA (2002) Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 67:267–274CrossRefPubMed
6.
go back to reference Brown KE (2005) Parvovirus B19. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 6th edn. Elsevier Churchill Livingstone, Philadelphia, pp 1891–1896 Brown KE (2005) Parvovirus B19. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 6th edn. Elsevier Churchill Livingstone, Philadelphia, pp 1891–1896
7.
go back to reference Corcioli F, Zakrzewska K, Rinieri A, Fanci R, Innocenti M, Civnini R, De Giorgi V, Di Lollo S, Azzi A (2008) Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. J Med Virol 80:2005–2011CrossRefPubMed Corcioli F, Zakrzewska K, Rinieri A, Fanci R, Innocenti M, Civnini R, De Giorgi V, Di Lollo S, Azzi A (2008) Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. J Med Virol 80:2005–2011CrossRefPubMed
8.
go back to reference Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, Klenerman P, Tolfvenstam T, Bowness P (2005) Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med 2:e343CrossRefPubMed Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, Klenerman P, Tolfvenstam T, Bowness P (2005) Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med 2:e343CrossRefPubMed
9.
go back to reference Isa A, Lundqvist A, Lindblom A, Tolfvenstam T, Broliden K (2007) Cytokine responses in acute and persistent human parvovirus infections. Clin Exp Immunol 147:419–425CrossRefPubMed Isa A, Lundqvist A, Lindblom A, Tolfvenstam T, Broliden K (2007) Cytokine responses in acute and persistent human parvovirus infections. Clin Exp Immunol 147:419–425CrossRefPubMed
10.
go back to reference Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed
11.
go back to reference Garn H, Renz H (2007) Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology 212:441–452CrossRefPubMed Garn H, Renz H (2007) Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology 212:441–452CrossRefPubMed
12.
go back to reference Ponsonby AL, van der Mei I, Dwyer T, Blizzard L, Taylor B, Kemp A, Simmons R, Kilpatrick T (2005) Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 293:463–469CrossRefPubMed Ponsonby AL, van der Mei I, Dwyer T, Blizzard L, Taylor B, Kemp A, Simmons R, Kilpatrick T (2005) Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 293:463–469CrossRefPubMed
13.
go back to reference Walsh SJ, DeChello LM (2001) Excess autoimmune disease mortality among school teachers. J Rheumatol 28:1537–1545PubMed Walsh SJ, DeChello LM (2001) Excess autoimmune disease mortality among school teachers. J Rheumatol 28:1537–1545PubMed
14.
go back to reference Slater CA, Davis RB, Shmerling RH (1996) Antinuclear antibody testing: a study of clinical utility. Arch Intern Med 156:1421–1425CrossRefPubMed Slater CA, Davis RB, Shmerling RH (1996) Antinuclear antibody testing: a study of clinical utility. Arch Intern Med 156:1421–1425CrossRefPubMed
15.
go back to reference Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511CrossRefPubMed Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511CrossRefPubMed
Metadata
Title
Gender differences in the relationship of anti-parvovirus B19 IgG with antinuclear antibody and C-reactive protein in clinical adult serum samples
Authors
Thomas A. O’Bryan
Stanley J. Naides
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1262-3

Other articles of this Issue 4/2010

Rheumatology International 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.